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Abstract
Background: Mortality rates in the Intensive Care Unit and subsequent hospital mortality rates
in the UK remain high. Infections in Intensive Care are associated with a 2–3 times increased risk
of death. It is thought that under conditions of severe metabolic stress glutamine becomes
"conditionally essential". Selenium is an essential trace element that has antioxidant and anti-
inflammatory properties. Approximately 23% of patients in Intensive Care require parenteral
nutrition and glutamine and selenium are either absent or present in low amounts. Both glutamine
and selenium have the potential to influence the immune system through independent biochemical
pathways. Systematic reviews suggest that supplementing parenteral nutrition in critical illness with
glutamine or selenium may reduce infections and mortality. Pilot data has shown that more than
50% of participants developed infections, typically resistant organisms. We are powered to show
definitively whether supplementation of PN with either glutamine or selenium is effective at
reducing new infections in critically ill patients.
Methods/design: 2 × 2 factorial, pragmatic, multicentre, double-blind, randomised controlled
trial. The trial has an enrolment target of 500 patients. Inclusion criteria include: expected to be in
critical care for at least 48 hours, aged 16 years or over, patients who require parenteral nutrition
and are expected to have at least half their daily nutritional requirements given by that route.
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Trials 2007, 8:25 http://www.trialsjournal.com/content/8/1/25Allocation is to one of four iso-caloric, iso-nitrogenous groups: glutamine, selenium, both glutamine
& selenium or no additional glutamine or selenium. Trial supplementation is given for up to seven
days on the Intensive Care Unit and subsequent wards if practicable. The primary outcomes are
episodes of infection in the 14 days after starting trial nutrition and mortality. Secondary outcomes
include antibiotic usage, length of hospital stay, quality of life and cost-effectiveness.
Discussion: To date more than 285 patients have been recruited to the trial from 10 sites in
Scotland. Recruitment is due to finish in August 2008 with a further six months follow up. We
expect to report the results of the trial in summer 2009.
Trial registration: This trial is registered with the International Standard Randomised Controlled
Trial Number system. ISRCTN87144826
Background
Intensive care unit (ICU) and subsequent hospital mortal-
ity in the UK remains high, with figures of 15–20% and
30% respectively [1]. The cost per ICU bed-day exceeds
£1,100 based on a mean from all trusts in England and
Wales [2]. In many countries, including the UK, provision
of intensive care is inadequate to meet demand. Infections
acquired on the ICU have been associated with a two to
three fold increased risk of death [3], this is associated
with both illness and drug related impairment of the
patient's immune system. Multiple portals for infection
include: tracheal tubes, nasogastric tubes, chest and
abdominal drains, central venous, pulmonary arterial and
urinary catheters, wounds, and infective loci present
before admission to ICU. These infections increase mor-
tality, morbidity, length-of-stay, antibiotic usage and costs
of care. As a result 40–50% of patients on ICU are pre-
scribed antibiotics at any one time [2]. Such concentrated
antibiotic usage may contribute to ICU, hospital and even
community antibiotic resistance, which is a major health
care issue [2,4-6].
A European point prevalence study in ICUs showed that
66% of patients were receiving artificial nutritional sup-
port, 42% of whom were receiving either parenteral nutri-
tion alone (23%) or parenteral combined with enteral
nutrition (19%). [7].
Although the enteral feeding route is preferred to
parenteral (reduced costs of administration and reduced
risk of infective complications from the intravenous line),
parenteral nutrition (PN) retains an important supportive
role in the management of ICU patients, many of whom
cannot be fed effectively by the enteral route because of
gastro-intestinal dysfunction [8].
Glutamine
Standard amino acid formulations do not contain any of
the amino acid glutamine, due to pharmaceutical stability
problems. In the past glutamine was considered a non-
essential amino acid therefore its omission from
parenteral nutrition preparations was not considered to
be a problem, as it was thought that the body would syn-
thesise its own. Glutamine has essential roles in acid-base
balance, nitrogen transport and maintaining muscle mass
and function, and is an energy source for rapidly dividing
cells, particularly those of the immune system and gut. As
the most abundant amino acid in the body, it is now rec-
ognised that glutamine synthesis and release is insuffi-
cient to meet demands under severe metabolic stress.
Glutamine must therefore be supplied from nutritional
sources if levels are to be maintained. Several studies have
shown that glutamine levels decrease markedly after
major surgery and during critical illness. Decreased serum
glutamine has been associated with immune dysfunction
in animal models and death or infectious complications
in septic patients. In randomised controlled trials (RCTs)
amongst patients, glutamine-supplemented PN has been
associated with improved nitrogen balance, higher intra-
muscular glutamine levels, improved mood, enhanced
immune cell function and no elevation of proinflamma-
tory cytokine profile [9-14]. In animal models glutamine
enhances intracellular glutathione (which combats free
radical tissue damage) [15]. Such effects of glutamine sup-
port on the stressed immune system in the patient receiv-
ing critical care could lead to 'successful inflammation', i.e.
the ability to combat infection, and decrease the systemic
inflammatory response syndrome, where excessive free
radical induced damage occurs.
Thus provision of glutamine could be of considerable
benefit in metabolically stressed critically ill patients.
Although the proposed benefits are biologically plausible
it is unclear whether they will be obtained in practice and
there is a danger that glutamine-containing PN solutions
will be incorporated into practice without adequate eval-
uation, thus our evaluation is timely.
Selenium
Selenium is an essential trace element found in a group of
proteins known as selenoproteins and which is present in
only modest amounts within standard PN solutions. Sele-Page 2 of 14
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reductase is involved in anti-oxidant defences, and also
has anti-inflammatory properties [16,17] mediated by
inhibition of lipid peroxidation. Selenium is also essential
to the production of thyroid hormones [18]. It is notewor-
thy that populations in many areas of Europe, including
Scotland, are relatively selenium deficient [17]. Given the
widely documented immunosuppression of critical ill-
ness, and its correlation with mortality and the purported
roles of reactive oxygen species in sepsis, pancreatitis,
organ dysfunction and other inflammatory conditions, it
is biologically plausible that enhanced selenium supple-
mentation could also be of benefit to the critically ill ICU
patient requiring parenteral nutrition.
It can be seen from the above background that both
glutamine and selenium have the potential to influence
the immune system, through different sites in biochemi-
cal pathways. Thus a factorial design for the proposed RCT
is appropriate to test the two hypotheses.
Systematic reviews
A systematic review of glutamine supplementation in crit-
ically ill (including following major surgery) adults [19]
found 14 small RCTs reporting data from 737 patients on
mortality, infectious complications, and length of hospi-
tal stay. When both parenteral and enteral routes of sup-
plementation are combined, complications were lower in
the glutamine group (risk ratio 0.81, 95% CI 0.67 to
0.99). There was also a trend towards a reduction in mor-
tality (risk ratio 0.79, 95% CI .59 to 1.04) and reduced
length of hospital stay, especially for surgical patients.
A more recent systematic review using random effects
methods of meta-analysis [20] found that parenteral
glutamine in critical illness was associated with a relative
risk for mortality of 0.75 (95% CI 0.52 to 1.07) and for
infection of 0.71 (95% CI 0.49 to 1.05). There was how-
ever, evidence of publication bias in the reporting of par-
ticipants' infections. The existing evidence is suggestive of
a positive role for glutamine supplementation but a fur-
ther large trial is required to determine whether any differ-
ences are statistically and clinically important.
A Cochrane systematic review of selenium supplementa-
tion in critical illness, has identified seven randomised
controlled trials of sodium selenite supplementation in
critical illness [21]. Five trials examined the effect of addi-
tional selenium supplementation on mortality at 28 days,
and showed a reduction trend in those supplemented
with selenium (relative risk 0.71, 95% CI 0.43 to 1.17,
random effects model). The relative risk for mortality,
whenever determined, for general intensive care patients
was 0.75 (95% CI 0.59 to 0.96, random effects model).
Based on reported information, these were poor quality
trials. Indeed, only one clearly reported concealment of
allocation and a further three trials undertook intention
to treat analysis.
In a systematic review of antioxidant nutrients in critical
illness, Heyland and colleagues [22] found that selenium
supplementation (alone and in combination with other
antioxidants) may be associated with reduced mortality
(RR 0.59, 95% CI 0.32 to 1.08). Clearly, a larger trial to
examine the clinical effects of additional selenium supple-
mentation in this patient group is required.,
Pilot Study
The purpose of the pilot study was to test the full protocol
with the aim of assessing feasibility and refining PN stock
management. It was carried out in two Scottish centres;
Aberdeen and Edinburgh. Patients enrolled to the pilot
study were recruited and processed in the same manner as
the full trial and we plan to analyse these data in the final
data set.
Methods and Design
The questions which this protocol will address
The questions which this trial will address
• Does the inclusion of glutamine, additional selenium or
the two in combination, in a standard preparation of PN
improve the outcome for critically ill patients particularly
in terms of participants with infections, mortality, ICU
and acute hospital stay?
• Is supplementation of PN with glutamine, additional
selenium, or the two in combination cost-effective?
Trial recruitment
The trial will involve people expected to be on intensive
care and high dependency units (levels 2 and 3 care)
under the care of the intensive care unit consultants for at
least 48 hours, aged 16 years or over, who require
parenteral nutrition and are expected to have at least half
of daily nutritional requirements given by that route.
Pregnant women and people whose expected stay in the
UK is less than six months will not be considered for the
study. Patients with severe renal failure (creatinine clear-
ance < 10 ml/min and not on renal replacement therapy)
will also be excluded.
In the case of hepatic failure, metabolism by the liver is
the main route of elimination for many drugs and nutri-
ents, but the hepatic reserve appears to be large and liver
disease has to be severe before important changes occur.
Routine liver function tests (LFTs) are a poor guide to the
capacity of the liver to metabolise drugs, and it is not pos-
sible to predict the extent to which the metabolism of a
particular drug or nutrient may be impaired. EnrolmentPage 3 of 14
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ever, caution will be advised when:
1. A 3-fold increase in LFTs above baseline for the patient
is seen.
2. Any derangement in liver synthetic function is noted.
Intensive care unit staff (doctors or nurses) based in each
clinical centre will identify potential participants. A log
will be kept of patients meeting the inclusion criteria,
describing the reasons if they are not subsequently
recruited to the trial. The recruitment procedure to be fol-
lowed is detailed in the SIGNET trial handbook (version
4 15-03-06).
Informing potential participants about the trial
If the patient is able to give consent, ICU staff (doctors or
nurses) will describe the study, backing oral information
with the standard study information leaflet. If, as is more
likely, the patient will be unable to give consent, intensive
care unit staff will describe the study to relatives of the
patient, backing oral information with the standard study
information leaflet.
Consent to participate
Once eligibility has been confirmed, authorised person-
nel will ask if the potential participant is ready to decide
whether or not to join the trial. If so, she/he will give the
participant a consent form. After the doctor or nurse has
checked that the consent form is understood, the nurse or
doctor will invite the participant to sign the form, then
will add their own name and countersign it. In the case of
relatives giving assent, the same procedure will be fol-
lowed using the consent form. Copies of the signed con-
sent form and information sheet will be placed in the
hospital notes. If the participant subsequently becomes
able to give consent, after assent has been obtained from
the relative, the study will be described to the participant
using the information sheet and consent form.
If the relative is not present and cannot attend the ICU to
sign the written assent within 24 hours of the patient
requiring PN, but is prepared to grant assent based on the
information read out to them over the phone and subse-
quent discussion, verbal assent will be recorded. Written
record of assent at a later time will be obtained if feasible.
In all cases a written information sheet will be provided
when they attend or a copy sent to them by post if they are
unable to attend. Separate consent forms for verbal con-
sent have been prepared.
In the unlikely event that there is no personal legal repre-
sentative (next of kin) it is possible to recruit the patient
to the study, provided a professional legal representative
(or equivalent in England, Wales or Ireland) has been
appointed by the hospital for that person.
Information collected at trial entry
Once a participant has agreed to join the trial, ICU staff
will record on a standard form:
1. Identifying and contact information
• Full name, address, telephone number
• Date of birth, age on recruitment day, sex
• NHS, hospital number and Community Health Index
number (if available)
• Marital status, woman's maiden name
• Name of a 'best contact', such as a friend or relative, with
contact details
• General Practitioner's contact details
2. Descriptive information
• Under-nourished, normal or obese, based on subjective
clinical assessment [23]
• Patient groups – medical, or surgical (including
trauma))
• APACHE (Acute Physiology and Chronic Health Evalu-
ation) II score
• SOFA (Sequential Organ Failure Assessment) score
• Severe sepsis or septic shock
• Antibiotics/anti-infectives on recruitment
This information will be sent to the Trial Office.
Trial interventions
The trial will use a 2 by 2 factorial design to test not only
whether glutamine and selenium on their own are effec-
tive, but also whether there is extra effectiveness from the
combination.
For this reason allocation will be to one of four groups, see
table 1.
All formulated PN bags (1500 ml volume) are isonitroge-
nous and isocaloric and have been tested for long-term
stability by Fresenius-Kabi. Standard additions of fluid,
electrolytes, vitamins and minerals will be allowed
(including standard doses of selenium). dditional nitro-
gen and/or energy will not however, be allowed in the PNPage 4 of 14
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Supplementation will be given for seven days only (on
ICU and subsequent wards and hospitals if practicable).
Once the decision is made to commence PN, it is desirable
that SIGNET PN is given from the start. If this is not pos-
sible SIGNET PN should be started within 48 hours of
commencing PN on ITU or HDU. If SIGNET PN is discon-
tinued for any reason, e.g. line removed, SIGNET PN can
be restarted within 48 hours from discontinuation and a
total of 7 days of SIGNET PN may be given. Patients who
have been given PN outside of critical care are eligible for
recruitment. A patient may be recruited to the trial only if
the pharmacy has sufficient stock for 5 days of bags of PN
at the start of therapy.
The volume of feed may be reduced for men under 60 kg
in weight and women under 70 kg. Consultants on inten-
sive care may opt not to enter patients into the trial if they
perceive the patient either to be at risk of refeeding syn-
drome, or to require a gradually phased introduction of
nutrition support.
Patients entered in the trial will be monitored as is stand-
ard practice in the ICU.
Treatment allocation
The existing central randomisation service (fully auto-
mated computerised telephone randomisation) in the
Health Services Research Unit at the University of Aber-
deen will be used to randomise patients. Recruiting staff
will telephone the randomisation line and will be asked
to key in details of identification and important prognos-
tic factors (see below), when confirming eligibility and
consent. Consent procedures will adhere to the 2003
Mental Health (Care and Treatment) (Scotland) Act. Ran-
dom allocation to one of the four possible treatment com-
binations (see above) will be minimised on trial centre;
age (<65 years or ≥ 65 years); sex; patient groups (medical
or surgical (including trauma)); and, patient nutritional
status (under-nourished, normal or obese – subjective
clinical assessment [24]. A four digit number for that
patient will be provided by the automated randomisation
service, the research nurse accessing the randomisation
service will then inform the centre pharmacy of this ran-
domisation number. The trial office, based at the Univer-
sity of Aberdeen will have provided each pharmacy with a
list of these random numbers linked to one of the four
treatment allocations, thus maintaining the blinding of
local investigators to the trial treatment. Figure 1 summa-
rises these arrangements.
Subsequent arrangements
Informing key people
Following formal trial entry, the Trial Office or local
research nurse will also contact:
• the consultant and ward staff caring for the patient on
discharge from the intensive care unit – informing them
of participation in the trial and the possible continuation
of trial treatment.
• the general practitioner – informing the GP practice of
participation in the trial and the (few) implications for the
practice. This letter includes a brief description of the trial
together with a request that the general practitioner noti-
fies the Trial Office if the patient dies.
• the 'best contact' asking for assistance to complete the
questionnaires (see below)
Additional information sought by post at three and six 
months after entry
Questionnaires will be sent to participants by post at three
and six months post randomisation, which will contain:
i) The SF-12 questionnaire and the EQ-5D questionnaire
ii) Contacts with health services after discharge
A cost questionnaire will also be sent to participants by
post at 6 months to elicit
(i) Costs to patients and carers (travel costs, time spent
travelling and attending appointments, time lost from
usual activities)
Participants will be sent up to two reminders by post if the
questionnaires are not returned to the Trial Office.
Table 1: The trial will use a 2 by 2 factorial design to test not only whether glutamine and selenium on their own are effective, but also 
whether there is extra effectiveness from the combination. For this reason allocation will be to one of four groups.
No glutamine Glutamine
No additional selenium Standard PN bag 12.5 g nitrogen, 2000 kcal daily PN bag, 12.5 g nitrogen (including 20.2 g glutamine), 2000 
kcal daily
Additional selenium Standard PN bag 12.5 g nitrogen, 2000 kcal daily 500 
µg selenium daily
PN bag, 12.5 g nitrogen (including 20.2 g glutamine), 2000 
kcal daily 500 µg selenium dailyPage 5 of 14
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and six months, questionnaires will not be sent to their
home address. Instead the trial office will ask the study
nurse or the staff looking after the participant to assist the
participant in completing the questionnaires, if appropri-
ate.
Notifications by general practitioners
A letter and information sheet will ask the general practi-
tioner to notify the Trial Office by telephone if the partic-
ipant dies (and to give cause of death).
Notifications by 'best contact'
A brief letter and freepost envelope will be sent to the 'best
contact' (relative that gave assent) at the time of the par-
ticipant's hospital discharge. The letter will ask if he/she
could assist the participant to complete the three and six
month questionnaires if this is appropriate.
Role of study nurses following recruitment
Data collection
At least ten critical care units will be involved in the SIG-
NET trial. Potential trial sites listed in the ethics applica-
tion are: Aberdeen Royal Infirmary, Western General
Edinburgh, Royal Infirmary of Edinburgh, Western Infir-
mary Glasgow, Ninewells Hospital Dundee, Stirling Royal
Infirmary, Dumfries and Galloway Royal Infirmary, Mon-
klands Hospital Coatbridge, Southern General Hospital
Glasgow, Victoria Infirmary Glasgow, Royal Alexandra
Hospital Paisley, St John's Hospital Livingston, Queen
Trial FlowsheetFigure 1
Trial Flowsheet. Randomised trial of glutamine and selenium supplemented parenteral nutrition for critically ill patients.
ICU staff decide to start PN for patient

Inclusion criteria checked for patient by ICU staff
(aged 16y or older; at least half nutritional needs likely to be met by PN; expected to
be in intensive care for at least 48 hours; expected stay in UK > 6 months)
patient excluded if pregnant; severe renal failure < 10ml/min and not on renal
replacement therapy

If patient eligible for the trial and not excluded

Authorised ICU staff/research staff obtain informed consent or assent from relatives

Research nurse phones central Trial Office giving details needed for randomisation
(trial centre, age, sex, patient group (medical or surgical), nutritional status
(subjective assessment))

Patient randomised (adopting factorial design) to either normal feed only, glutamine
supplementation only, selenium supplementation only or glutamine AND selenium
supplementation
(all formulated PN bags (1500ml volume) are isonitrogenous and isocaloric)

Research nurse contacts hospital pharmacy directly to give allocation number
(retaining blinding)

Pharmacy prepares PN for ICU and liaises with PN supplier for needs

Patient on ICU receives PN, research nurse ensures data is recorded and sent to Trial
Office,
routine data processed via SICS database

Trial supplementation ceases after 7 days (or earlier if PN stopped for clinical reason)

Research nurse collects in-hospital and discharge information and sends to Trial
Office

Patient questionnaire sent at 3 and 6 months from Trial OfficePage 6 of 14
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Inverness. The SIGNET trial will start initially in the pilot
sites, Aberdeen Royal Infirmary and the Western General
Hospital in Edinburgh along with Ninewells Hospital,
Dundee. The study may be extended to include sites out-
side Scotland if this is considered necessary in which case,
possible sites include Cardiff Royal Infirmary, Belfast
Royal Infirmary, and Newcastle Royal Infirmary.
The study nurse will ensure that data are fully collected for
participants. The study nurse will also collect data needed
for secondary care resource use (e.g. length of stay in ICU,
HDU and general wards from hospital case notes.)
If the Trial Office fails to make contact
The Trial Office will liaise with the local study nurse if
there is ever failure of contact with a participant. In these
circumstances the nurse or Trial Office will telephone the
general practitioner's (GP's) surgery to check vital status
24–48 hours before telephoning the participant. If the GP
refuses to disclose this information, the patient will not be
contacted.
Routine data collection
Information on subsequent hospital admissions and
deaths will be collected by registration with the Informa-
tion and Statistics Division Scotland (ISD) and the
National Office of Statistics (ONS) and NHS Central reg-
isters
Data collection and processing
Data from the various sources outlined above will be sent
to the Trial Office in the University of Aberdeen for
processing. Staff in Aberdeen will work closely with study
nurses to secure as complete and accurate data as possible.
A random 10% sample of data will be double entered to
check accuracy. Extensive range and consistency checks
will further enhance the quality of the data.
Analysis plans
Ground rules for the statistical analyses
The statistical analyses will be based on all people ran-
domised, irrespective of subsequent compliance with
nutritional support. The principal comparisons will be:
(i) all those randomised glutamine versus all those not
allocated glutamine
(ii) all those randomised selenium versus all those not
allocated selenium
(iii) all randomised glutamine and selenium versus all
randomised glutamine alone versus all randomised sele-
nium alone versus all randomised placebo
Evidence will be sought for an interaction between
glutamine and selenium.
Measures of outcome
Primary
• Mortality – on ICU and HDU and overall at six months
• Infections – counted as participants with new reported
infections and Centres for Disease Control (CDC) con-
firmed infections in the first 14 days [25].
Secondary
• ICU and HDU length of stay and acute hospital length
of stay
• Days of antibiotic usage;
• Duration of PN usage;
• Alive, ventilator-free days as recommended by Ruben-
field [26];
• Change in SOFA scores;
• Serious Adverse events (excluding deaths) (for reporting
of Suspected Serio-s Adverse Reactions (SSARs) and Sus-
pected Unexpected Serious Adverse Reactions (SUSARs).
• Patient quality of life measured by SF12 and EQ5D; and
• Costs to the NHS, patients and carers/families; incre-
mental cost per day in ICU saved and/or per quality
adjusted life years (QALYs)
Timing and frequency of analyses
A single principal analysis is planned six months after the
last person is recruited. If considered appropriate, follow-
up of recruits will be extended at this time. The Data Mon-
itoring Committee (DMC) (see below) will determine the
frequency o- confidential interim analyses.
Secondary sub-group analyses
Planned subgroup analyses include:
(i) Under-nourished, normal or obese;
(ii) Patient groups (medical, or surgical (including
trauma));
(iii) Age <65 or ≥ 65;
(iv) Evaluation by the severity of illness, including;
APACHE II and SOFA scores, above and below mean or
median score; andPage 7 of 14
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Stricter levels of statistical significance (2p < 0.01) will be
sought, reflecting the exploratory nature of these sub-
group analyses. The Chi-squared test for heterogeneity
will be used to explore any apparent differential effects.
Economic analysis
The underlying aim is to keep economic data collection as
parsimonious as possible to minimise the burden upon
trial participants and participating centres. Data on costs
to the NHS including treatments, investigations and con-
sultations will be collected as part of the economic evalu-
ation. The type of economic evaluation performed will
depend upon the findings [23]. Both deterministic and
stochastic sensitivity analysis [27] will be used to explore
the importance of the uncertainty surrounding estimates
of effectiveness, cost, and cost-effectiveness/utility. NHS
resource use will be costed using appropriate unit costs.
These will be taken from published sources (e.g. drug
costs from the British National Formulary and GP cost
from published estimates [28], manufacturers' list prices
(e.g. consumables, equipment)) or using study-specific
estimates. QALYs will be calculated using the EQ5D scores
[29]. The EQ5D has been successfully used to measure
changes in quality of life in patients discharged from ICU
[30].
Power calculation
The primary endpoint for the trial is the proportion of
patients acquiring infection(s) after starting trial PN. Sys-
tematic reviews indicate that the reduction in proportion
of patients acquiring infections in previous trials ranged
from approximately 50% in the control arm to 40% in the
intervention arm. Removing Griffiths' glutamine trial
[31,32] – which only reported infections in a post-hoc
analysis – shows the effect may indeed be greater (from
50% in the control arm to 30% in the intervention arm).
A plausible reduction to detect would be the midpoint of
these two estimates (i.e. a reduction from 50% to 35%),
hence 340 participants would be required to detect this
size of difference (with 80% power and 2p < 0.05) [33].
Given the high mortality rates in critical care patients [1],
we have allowed for potential loss of patients to follow-up
over the six months (see below – this would primarily
affect secondary outcomes such as quality of life meas-
ures). We have consequently inflated the sample size
requirement by approximately 20%, thus plan to recruit
500 patients to the trial.
Based on routine data available from the Scottish Inten-
sive Care Society (SICS) audit database, the average length
of ICU stay for patients receiving PN is approximately 9
(SD 7) days. For a 2 day reduction in ICU stay to be
detected, with 80% power and 2p < 0.05, a trial of approx-
imately 400 patients would be required. As we do not
expect any dropout from the trial prior to discharge, we
are adequately powered to detect this level of change.
A trial with 500 patients would allow us to detect a quarter
of a standard deviation (0.25SD) change in hospital
length of stay with 80% power and 5% significance
(assuming all data for length of stay are available).
A trial of 340 patients would have 80% power and 5% sig-
nificance to detect differences in Quality of Life measures
of approximately 0.33SD (a third of a standard deviation
change) or 90% power to detect a 0.5SD change. Previous
research in the behavioural field suggests that a 0.5SD
change is the level of change that should be associated
with a moderate change in quality of life measures
[34,35]. As such we are well powered to detect meaningful
changes in quality of life measures.
Recruitment rates
Approximately 900 patients per annum receive PN in
Scottish Intensive Care Units (source: SICS audit data-
base). Assuming a conservative recruitment rate – that we
recruit a third of eligible patients – we expect to recruit the
500 patients required within a two-year recruitment
phase.
Data analysis
Analysis of dichotomous outcomes will be analysed using
statistical tests such the Chi-squared test. Continuous
measures will be analysed using t-tests (with transforma-
tion of data to Normality if appropriate), or non-paramet-
ric equivalents. A further analysis accounting for the inter-
relationship between deaths and length of stay will be
undertaken, akin to that described for ventilator-free days
by Rubenfield [26] mentioned earlier. This, for example,
would allow the apparently short length of stays associ-
ated with early deaths to be accounted for appropriately.
A significance level of 2p < 0.05 will be considered as evi-
dence of statistical significance for the primary outcomes.
Confidence intervals will also be presented where appro-
priate. The economic analysis will incorporate sensitivity
analysis, and confidence intervals will be constructed
around stochastic cost data using techniques such as boot-
strapping [27].
Organisation
Local organisation
Each collaborating centre will identify a principal investi-
gator. The responsibilities of this person will be to:
1. establish the trial locally (for example, by getting agree-
ment from clinical colleagues, facilitating local research
ethics committee and trust approval; identifying andPage 8 of 14
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ical staff on ICU and the hospital pharmacy are aware of
this trial)
2. agree to follow the trial protocol and to ensure that all
team members on his/her site understand their obliga-
tions and to conduct the trial to GCP requirements
3. ensure that all study site personnel are adequately
trained and qualified to carry out their delegated respon-
sibilities and provide support and supervision to these
personnel
4. agree not to start the trial until Main REC, LREC and
local management approval is given
5. retain all documentation associated with the trial and
all documentation sent by the Chief Investigator or Spon-
sor of the trial
6. report deviations from the protocol to the Chief Inves-
tigator
7. report any safety issues to the Chief Investigator
8. take responsibility for clinical aspects of the trial locally
(for example, if any particular concerns emerge)
9. notify the Trial Office of any unexpected clinical events
which might be related to trial participation
10. report serious adverse events to the Chief Investigator
within 24 hours of the Principal Investigator knowing of
the serious adverse events
11. provide support and supervision for the local study
nurse
12. represent the centre at collaborator's meetings
Each clinical centre may appoint a study nurse to co-ordi-
nate the day to day aspects of the trial. The responsibilities
of this person will be to:
1. keep local staff informed of progress in the trial
2. keep regular contact with the local principal investiga-
tor, with notification of any problem or unexpected devel-
opment
3. maintain regular contact with the Trial Office
4. identify potential participants and keep a log of
whether or not they are recruited (with reasons for non-
participation)
5. liaise with PN team
6. check eligibility, give information about the trial, and
seek consent
7. randomise patients and obtain randomisation code
8. liaise with the hospital pharmacy
9. collect data describing participants, and send these to
the Trial Office
10. liaise with consultants on other wards after patients
have been discharged from ICU
11. record outcome measures on study CRFs
12. send study CRFs to Trial Office no more than eight
weeks after each patient has been recruited
13. clarify the situation when the Trial Office fails to make
a contact with a local participant, getting in touch by tele-
phone
14. seek further clinical details when a major trial event
(such as a hospital admission or death) is reported to the
Trial Office, even if this occurs in another hospital
15. provide support for participants in other ways if there
are difficulties
16. represent the centre at trial nurse meetings and collab-
orators meetings
Each clinical centre will designate study pharmacist(s) to
co-ordinate the day-to-day pharmacy aspects of the trial.
The responsibilities of the local pharmacists will be to:
1. allocate treatment for the patient according to the
assigned randomisation code using the SIGNET randomi-
sation schedule
2. ensure the allocation is checked by a pharmacist (other
than ICU pharmacist if possible)
3. formulate the PN according to prescription, stability
information and hospital SOPs
4. label bags appropriately to ensure blinding of treatment
allocation is maintained at ward level
5. ensure that clinical trials pharmacists and aseptic phar-
macists are the only personnel on site unblinded to treat-
ment allocationPage 9 of 14
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nium if applicable on the accountability log
7. record the use of bags after every patient has completed
their SIGNET PN on the pharmacy stock control website
8. ensure that all study site pharmacy personnel are ade-
quately trained and qualified to carry out their delegated
responsibilities and provide support and supervision to
these personnel
9. manage stock levels to ensure sufficient stock of both
glutamine and non glutamine bags to provide seven days
of SIGNET PN when patient recruited
10. ensure that the storage conditions of the Signet Study
PN bags are adhered to
11. ensure that there is stability data available for all vari-
ations in the electrolyte profiles of the Signet Study PN
bags that are used
12. retain all documentation associated with the trial for
example patient worksheets, completed prescriptions,
study drug accountability logs, shipping receipt, destruc-
tion or disposal documentation, temperature control logs
and all documentation sent by the Chief Investigator or
Sponsor of the trial
13. report deviations from the protocol to the Principal
Investigator
14. report any safety issues to the Principal Investigator
Trial co-ordination
The Trial Office
The Trial Office is in the Centre for Healthcare Ran-
domised Trial (ChaRT), in the University of Aberdeen,
which gives day-to-day support to all clinical centres. It is
responsible for collection of data (in collaboration with
the local study nurses), data processing and analysis. It is
also responsible for randomisation and unblinding, (as
clinically necessary). The trial coordinator is based in
Edinburgh and will supervise the day-to-day conduct of
the trial under the direction of the Chief Investigator and
the Director of CHaRT. The Trial Office will be responsible
for submitting annual reports to MREC, MRC, and regular
reporting of SSARs and SUSARs to MREC and MHRA. It
will also produce progress reports to both the Trial Steer-
ing Committee, and unblinded interim reports to the
Data Monitoring Committee (DMC).
There will be four staff directly located in the central Trial
Office – the data manager/secretary, the statistician, the
economist and the programmer. These staff members will
be supported by senior members of CHaRT (The Director,
the Senior Trial Manager and the Senior IT Manager and
by the Director of HSRU and grantholder). The trial co-
ordinator will be based in the University of Edinburgh but
will be in day to day contact with the trial office and will
be collocated in the trial office four days a month.
The trial co-ordinator will take overall responsibility for the
day to day conduct of the trial, including supervision of all
trial staff, visiting all centres and working with the local
ICU investigators to establish the trial, providing regular
liaison with the research nurses, arranging all trial meet-
ings, and reporting to the project management group. The
data manager/secretary will be responsible for all aspects of
data collection and processing, including processing of
trial entry data, data entry, questionnaire monitoring,
chasing missing information, and follow-up of non-
responses. The programmer will establish a database man-
agement system for efficient conduct of the trial including
the randomisation, timely despatch of questionnaires,
automatic form monitoring, data validation and cleaning.
The statistician will undertake all statistical tasks in the
study including the formal analysis and reporting of the
data, progress reports to the Study Committees at study
end, all under the supervision of the Director of HSRU
(one of the grant holders).
A health economist will be responsible, under the supervi-
sion of the Senior Health Economist (one of the grant
holders), for the development of data collection forms
(such as the patient/carer time and travel questionnaire)
required for the economic evaluation; the unit costs of
health care resources; the analysis of the economic data;
and the preparation of the economic evaluation compo-
nent of the final report.
The Operations Management Group
The Operation Management Group will meet weekly at
the Trial Office in Aberdeen, to review day to day progress
and troubleshoot emerging issues. The Chief Investigator
via teleconference will routinely join them.
The Project Management Group
This consists of representatives from two of the clinical
centres, and representatives from the Trial Office. Observ-
ers may be invited to attend at the discretion of the Project
Management Group. This will meet regularly during the
trial – typically every 6–8 weeks face-to-face or via telecon-
ference.
The Trial Steering Committee
A Trial Steering Committee supervises the trial. This com-
mittee includes three independent members, together
with those originally granted funds to mount the trial.
Observers from the host University (University of Edin-Page 10 of 14
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Other members of the Project Management Group may
attend as observers at the invitation of the Chair of the
Steering Committee.
Data and safety monitoring
The Data Monitoring Committee
A DMC will be established. This will be independent of
the trial organisers. During the period of recruitment to
the trial, interim analyses will be supplied, in strict confi-
dence, to the DMC, together with any other analyses that
the committee may request. This may include analyses of
data from other comparable trials. In light of these inter-
imfindings, the DMC will advise the Trial Steering Com-
mittee if one or more of the randomised comparisons in
the trial has provided;
1. proof beyond reasonable doubt that for all or some
types of patients, one particular type of treatment is clearly
indicated in terms of a net reduction in participants with
infection without any increased risk of death or serious
complications (or clearly contraindicated because of a net
increase in length of stay or mortality)
2. evidence that might reasonably be expected to influ-
ence materially the care of people who require PN feeding
in ICU by clinicians who know the results of this and
comparable trials.
The Trial Steering Committee can then decide whether or
not to modify intake to the trial. Unless this happens,
however, the Trial Steering Committee, project manage-
ment group, clinical collaborators, and trial office staff
(except the study statistician who supplies the confiden-
tial analyses) will remain blinded from the interim results.
The frequency of interim analyses will depend on the
judgement of the chairman of DMC, in consultation with
the Trial Steering Committee.
Other safety concerns
The incidence of adverse effects from the proposed dosage
of glutamine and selenium is anticipated to be very low –
in the systematic reviews safety issues were not a concern.
Collaborators and participants may write to the chairman
of the Trial Steering Committee regarding any worries
they may have about the trial. If concerns arise about side
effects or particular types of participants, these will be
relayed to the Chairman of the DMC.
If clinically indicated, rapid unblinding of trial materials
will be available through the trial office.
The trial will be conducted according to the MRC Good
Clinical Practice Guidelines (1998), the Data Protection
Act 1998, and the ICH E6 GCP document.
Publication
The success of the trial depends entirely on the whole-
hearted collaboration of a large number of participants,
their relatives, nurses and doctors. For this reason, chief
credit for the trial will be given, not to the committees or
central organisers, but to all those who have wholeheart-
edly collaborated in the trial. The trial's publication policy
is described in detail in section 2 of the Site File and is in
accordance with the rules of the International Committee
of Medical Journal Editors. The results of the trial will be
reported first to trial collaborators. The main report will
be drafted by the Project Management Group, and circu-
lated to all clinical co-ordinators for comment. The final
version will be agreed by the Trial Steering Committee
before submission for publication, on behalf of the Col-
laboration. In this case the authorship will be presented
by the collective title – The SIGNET Trial Group – and the
article will carry a footnote of the names of the people
(and their institutions) represented by the corporate title.
For any additional publications (including conference
presentations) one or more authors may take responsibil-
ity for drafting the paper or abstract but all group mem-
bers qualify as members; in this case, this should be
recognised using the byline 'Jane Doe and the Trial
Group.' Group authorship may also be appropriate for
publications where one or more authors take responsibil-
ity for a group, in which case the other group members are
not authors but may be listed in the acknowledgement
(the byline would read 'Jane Doe for the Trial Group'). No
study or report can be published without the agreement of
the Project Management Group.
Once the main report has been published, a summary will
be sent to the GPs of participants involved in the trial and
to individual participants' or relatives' who have indicated
they would like to receive one.
Discussion
In 2002, the Medicines Control Agency provided exemp-
tion letters for Selenase T pro injection (sodium selenite)
supplied by Oxford Nutrition and for Dipeptiven sup-
plied by Fresenius-Kabi for this trial. Prior to the imple-
mentation of the EU Directive in 2004, the MHRA
confirmed that the exemptions would be rolled over to a
Clinical Trial Authorisation.
The development of the protocol, ethical, research and
development approvals had to negotiate the administra-
tive constraints of the European Directive on Clinical Tri-
als when applied to non-commercial trials.Page 11 of 14
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at recruiting centres required collaboration with a phar-
macy holding a license to compound the investigational
medicinal product. We are grateful to Tayside Pharmaceu-
ticals for their continued support and provision of 2
"base" bags of blinded parenteral nutrition, one with
glutamine and one without. The two PN base bags have a
90 day stability. Thus, transportation and stock manage-
ment are vital to the trial success and in particular, mini-
misation of wastage. Participating pharmacy departments
and the central supplier have access to a custom designed
website that has information on stock inventory, its shelf
life and site PN usage. When this is combined with a com-
prehensive, refrigerated delivery service and an emergency
contract with a national courier, PN supply has become
more efficient.
Addition of selenium and electrolytes by the individual
participating pharmacies allows SIGNET centres to recruit
patients with only a 5 day stock of 2 "base" bags of PN.
Debate exists as to whether the addition of selenium at
each centre constitutes a licensable action. Notably, sele-
nium is one of the 2 Investigational Medicinal Products
(IMPs) for this trial. A final decision is expected from
competent authority in due course.
Trial management is divided between Edinburgh where
the Chief Investigator and Trial Coordinator are based
and Aberdeen University where the trial office is based (as
described above). The University of Edinburgh is admin-
istering the MRC Grant. SIGNET is a multicentre trial and
the use of teleconferencing and the willingness of the cur-
rent TrialCo-ordinator to travel has made the arrangement
successful.
The EU clinical trials directive requests that each trial must
have an identified sponsor. NHS Lothian is the lead NHS
organisation and the Sponsor of the SIGNET trial with col-
laboration from the Centre for Healthcare Randomised
Trials (CHaRT), within the University of Aberdeen.
Increasing investment in trial supporting infrastructure
has facilitated trial monitoring and documentation for
site monitoring and source document verification. Phar-
macovigilance is managed by Aberdeen University as the
trial office has infrastructure and procedures in place for
reporting Suspected Unexpected Serious Adverse Reac-
tions (SUSARs).
The study is being conducted throughout Scotland and
involves patients in intensive care and high dependency
units. The collaboration and support of the staff in the
Critical Care areas is essential in running this study. There
are currently 10 sites in Scotland recruiting patients and to
date over 285 patients have been recruited.
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